Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Novelix Pharmaceuticals Ltd (NSE: NOVELIX), ISIN INE314I01036 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
NOVELIX last traded at ₹66.01 (-2.03%), with a 52-week range of ₹49.01 to ₹92.00 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 54.29%, FIIs 0.00%, DIIs 0.00%, mutual funds 0.00%.
EquiSense Score (ECS): 63/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.